Cytek Biosciences, Inc Investor Event Transcript, Nov 17, 2026
Cytek Biosciences, Inc. (CTKB)
Cytek's analyzer category sales were up more than 30% compared to a year ago, and gross margin improved 600 basis points from the Singapore manufacturing shift, lower tariffs and better material costs. AI summary
Conference Transcript - CTKB 2026-11-17
Mason Carrico, Analyst — Stephens
We'll go ahead and get started. Welcome, everyone, to day one of the Stevens Conference. I'm Mason Carrico. I'm the Diagnostics and MedTech Analyst here. Happy to have the SciTech team with us. We've got Wenbin Zhang and Bill McComb, CFO. Sorry, Wenbin, CEO. Bill, CFO. I guess where we can start is you guys just reported Q3. Maybe give us a quick overview of the quarter, and maybe more broadly discuss how 2026 played out, you know, versus your initial expectations given the backdrop.
Bill McCombe, CFO
Sure. So the highlights of the quarter were that our Aurora Evo revenue was extremely strong. Our analyzer category, which is Aurora, Aurora Evo, and Borealis, was up more than 30% compared to a year ago. So demonstrating very strong market reception, customer demand for those leading edge products that they're really the state of the art in flow cytometer analyzers. We also had a significant improvement in gross margin. We completed the transition of manufacturing capacity from Seattle to Singapore, and finally have closed our manufacturing activities in Seattle. We still have significant R&D there. And together with lower tariffs and better material costs, the combination of those three gave us a 600 basis point improvement in gross margin. And we were a service business continued to grow nicely with the install base. So we were pleased with all that. We did have some softness in the lower end instruments and in Asia Pacific that offset those gains. But we're very pleased with the strength of our high end portfolio in the marketplace. And we, you know, we expect that. That Asia-Pac will, you know, will stabilize. And the, it was up about 5% of Q2, but compared to very strong comps last year, caused it to be down year on year. I'd say generally. The quarter was fairly consistent with our expectations. You know, Asia-Pac was a little softer than we thought, but, you know, I'd say that's more of a timing issue than a second-world trend.
Wenbin Zhang, CEO
The U.S. market has done particularly well compared to the same period last year.
Mason Carrico, Analyst — Stephens
Yeah, which is fairly unique for the tool space right now, and we'll get to that. But I guess maybe to start on Evo, I think you guys said placements nearly doubled in the quarter. Maybe, and I get that we're on Evo too at this point, but maybe just talk about, you know, customer reception since that launched last year. What customer types are driving demand for that platform?
Wenbin Zhang, CEO
And I think for EVO and EVO2, EVO was originally designed really to aim for pharmaceutical company, biopharma, and EVO2 is an additional, with additional features for automation and cooling and to fit for the application and being received very well by the biopharma and the CIO. Of course, some of the university call lab are also interested in the technology and acquired some of the products. There's a particular interest that are from those pharma and the CIO.
Mason Carrico, Analyst — Stephens
And on EVO2, you added automation and throughput enhancements there. I guess, how much of the Q2 strength or Q3 strength was driven by EVO2?
Wenbin Zhang, CEO
EvoTool was a product just launched at Seido in June this year. So Q3 pretty much is the first quarter. We have seen the interest coming in, and we clearly will see more and more of those interest continuing on through next year.
Mason Carrico, Analyst — Stephens
How much of the legacy Aurora install base has been upgraded to Evo at this point? How much of an opportunity do you still have ahead there?
Wenbin Zhang, CEO
I think if you look at the customers for EVO, including EVO 2, there are a few categories. First is the new customers. Second part is those customers adding new features and new capabilities on top of what they have already acquired from EVO. The third category is to replace those installed base, not from Cytek, actually, from all those conventional flow cytometers. As you can see today, the whole industry has been shifted toward spectral flow cytometer, which we pioneered. We actually dominate right now in the market. And, of course, a very small portion of those are to replace the original instrument we placed in the field 10 years ago, since 10 years ago. So those are the kind of distributions, but replacing our own aurora is still a very small part of that.
Bill McCombe, CFO
We've only sold a couple of hundred ballpark EVOs in total, and the total flow cytomative population out there is 50,000. So we're, you know, just scratching the surface.
Mason Carrico, Analyst — Stephens
Got it. So when we think about kind of the ramp or, you know, just the strength and instrument placements from EVO over the, you know, since launch, how do you kind of break it down between new customers, fleet expansions, replacing, you know, an existing conventional flow cytometer? What makes up the majority of placements, you'd say?
Wenbin Zhang, CEO
I would say more than 50% are the new customers and also those adding additional capabilities on top of what they have, replacing conventional and also our instrument is still a very small part of that.
Mason Carrico, Analyst — Stephens
Okay. And how's the cell sorter demand been trending?
Wenbin Zhang, CEO
We launched Cell Soda in 2021 by now, already five years. Last few years, we have seen a clear growth on the Cell Soda. Part of the reason with that is because our Cell Soda is the only instrument out there in the field which matches our analyzer very well. The panels developed on the analyzer can move over to the solder and back and forth seamlessly. And that really enables the users to reduce their development time and improve their lab efficiency. So that's why CES has been very well received by our customer base. And we have seen this continue to grow over the last few years. And we feel this trend is going to continue.
Mason Carrico, Analyst — Stephens
And then maybe on the more recent launch, the Borealis, could you just walk through, I guess, what differentiates that platform compared to what's on the market today? Where is it drawing interest from a customer type? Where does it fit in the portfolio?
Wenbin Zhang, CEO
Borealis is our newest platform, which add additional two lasers onto our existing system, and because of this, that enables us to get to 60 color, and we could even go way beyond 60 color, which is the state of art today. And the limitation is by the available dyes out there on the market, and that's also a reason why when we launched Borealis, we actually launched the instrument together with the reagents we have developed at SciTech and as a full solution. What Borealis enables to do is not only being able to do the typical phenotyping, and it also adds the imaging capability on top of the conventional flow cytometry analysis. Yes, as you know, we have, uh, uh, Imaging flow cytometer, I'm next, but that one is based on the conventional flow cytometer capabilities with the Borealis that really bring us to the next level, and now we are able to do a high dimensional 6C color on top of this is with the imaging capability. This is actually kind of true imaging. It's better than all of those out there in the field and benchmark our own Omnix imaging technology. So that really enables us to facilitate lots of applications in the field, which people really want to look at, not only just the phenotype, but also look at the nanoparticle features, look at the cell-to-cell interactions. This is the kind of capabilities enabled by Borealis. On top of that, Borealis has also incorporated lots of the current state-of-art communication system enable remote monitoring, remote sensing, remote control, and those kind of capabilities.
Mason Carrico, Analyst — Stephens
And on that point of the dyes and kind of the 60-color performance, does that mean that Boreal should carry a higher reagent pull-through than the rest of your portfolio?
Wenbin Zhang, CEO
It depends on application. If Boreal is taking the full capability of that, yes, the answer is absolutely yes. But on the other hand, depending on the regular applications, many of the applications probably, if they don't really need to get to the 60 color or beyond, then it's pretty much similar as our EVO platform.
Mason Carrico, Analyst — Stephens
And then on the imaging capability, you talked about doubling the early access program in Q3, and you're going to continue to expand it in Q4 ahead of a broader launch next year. What milestones, I guess, do you still have to hit prior to that commercial launch? Is integrating imaging the gating factor right now into the timeline to launch?
Wenbin Zhang, CEO
Yes, the full launch will incorporate the full imaging capability currently aiming for the site of meeting next year.
Mason Carrico, Analyst — Stephens
Got it. And will every platform ship with imaging standard, or will that be an add-on?
Wenbin Zhang, CEO
Imaging actually is a standard, but if customers don't like imaging, we can scale down.
Mason Carrico, Analyst — Stephens
Okay, got it.
Bill McCombe, CFO
We've actually demonstrated the technology a couple of times at Saito last year and then recently at a conference in Japan.
Mason Carrico, Analyst — Stephens
Do you think Borealis cannibalizes some EVO purchases once launched, or do you view this as more additive in nature, where maybe it sits beside an EVO? How do you think about it?
Wenbin Zhang, CEO
No, actually, what distinguishes Borealis from EVO is, EVO is a daily workhorse for people who want to do a large quantity of studies, but on the other hand, Borealis has additional capability on top of this. Typically, this is a tool useful for those advanced research in academic institution, call labs, or pharma discovery, and in that case, and they really need The two additional superb capabilities to support the latest scientific studies. But on the other hand, EVO is for the daily applications. They are not going to replace each other.
Mason Carrico, Analyst — Stephens
Got it. How does the sales cycle of Borealis compare to EVO? I mean, maybe it's a little bit different because you're in the early access program. I'm not sure exactly, but just given, you know, kind of the backdrop, capital approvals for higher ticketed items. How's that compared to what you've seen from EVO? What are your expectations there?
Wenbin Zhang, CEO
As you have just mentioned, it's too early for us to judge right now because it's early access, and typically those labs who are having no lack of fun are interested in trying to assess.
Bill McCombe, CFO
Yeah, we don't see a big difference. I mean, labs are purchasing equipment that is higher ticket price than the Borealis, so. I don't think it should be any significantly slower. It's just, it's a new product, and the capabilities are much more advanced than EVO, so it takes a little bit longer for people to really understand what it can do. So perhaps it's a little longer in that respect. I wouldn't think it should be a material impact on revenue growth.
Mason Carrico, Analyst — Stephens
Got it. And from an early access standpoint, I guess, what does kind of the customer base look like today? Is it highly concentrated in North America?
Bill McCombe, CFO
No, no, it's global. It's North America, Europe, Asia as well. One significant point of differentiation that people may not be familiar with is that the only other imaging product on the market is the AASA, and when you turn on the imaging capability on one of those instruments, it cuts the throughput rate by two-thirds, so that's a significant limitation on productivity, and our technology doesn't require that. And what we've seen with EVO is that the EVO has doubled the throughput rate of the Aurora, and that's been one of the huge drivers of its success. So I think the same will apply.
Wenbin Zhang, CEO
And EVO actually is shown at Japanese immunology conference right now today. As I said this morning, I see a picture. Our booth is full of those people who are interested in our booth right now.
Mason Carrico, Analyst — Stephens
And kind of on that point of the install base, or the early access customer group, is it mainly pharma, CROs, CORs, like what does the customer mix look like from that standpoint?
Bill McCombe, CFO
I think it's a mix of both. We've seen it from, you know, we see both. We see some, you know, I'm looking at the pipeline here, some universities, some pharma companies. Yeah, I wouldn't, I think it's a balanced mix of both.
Mason Carrico, Analyst — Stephens
Where does production stand today, and will it, you know, will it be scaled to the point to meet demand at launch? Kind of, where do you stand in the scale-up of the production of that, or the assembly of that instrument?
Wenbin Zhang, CEO
We never had any problem with manufacturing, and, you know, since the full launch will be settled next year, we have plenty of time to get us ready.
Bill McCombe, CFO
Yeah, we've been working on this product for a couple of years.
Mason Carrico, Analyst — Stephens
So no issues? Yeah, no. Maybe on kind of the A&G point we hit on in the beginning, that's kind of been a standout for you guys this year, which is unique in the tool space, I would say. So at a high level, I guess, why has A&G, particularly in the U.S., been so strong for SciTech when many of the other tools names have consistently pointed to it as a point of weakness throughout the year?
Bill McCombe, CFO
Yeah, you know, A&G in the U.S. is up 60%, 6-0 this year over last. And the business mix has shifted. Traditionally, we were 60% farmer, 40% academic. In the U.S., we're actually 50-50. And I think... The leading research universities, who are our primary customer base, have a strong desire to have the very latest equipment. And if you come out with an exceptional new product like the Evo, which has all the features that we talk about, the high flow rate, the small particle detection, the automation, then the big universities just have to have it. These big core labs, the way universities are organized is they have a core flow lab that sort of rents out time to different departments. And it's important for the core lab to have the latest equipment. And I think we've benefited from that. And I think, you know, with Borealis, we'll see the same thing. So I think that's the driver. And obviously, the disruptions to funding from a lot that occurred early last year are now behind us. And the universities are confident of their funding situation.
Mason Carrico, Analyst — Stephens
Got it. So have you seen, I guess, on that point, things have obviously improved to some degree, right, compared to how has it played out, you know, quarter over quarter throughout this year? Have you seen pretty consistent?
Bill McCombe, CFO
Yeah, we had a really good, so last year, you know, obviously there was a lot of concern in the first and second quarter, and then NIH funding actually came back in Q, started to come back in Q2, came back in Q3, and then was quite strong in Q4, and then this year we've had a pretty good. And I think with the change in the Congress, the composition of the Congress coming up next
Mason Carrico, Analyst — Stephens
And then on Europe, ANG has been a bit softer, but I think you highlighted EMEA returned a 3% instrument growth.
Bill McCombe, CFO
Yeah, we had 3% growth in EMEA. Actually, A&G was stronger there in Q3. We had a big catch-up in Q4 of last year, but other than that, we had six or so quarters of negative growth in EMEA. It was actually seven quarters of negative growth, so it was good to see some returning to stabilization. And look, I think we got to the point where we hit rock bottom, and there are big universities and big research institutes in Europe, and they just have to keep up with the rest of the world. I think there's a natural floor there somewhere and hopefully we've hit that.
Wenbin Zhang, CEO
Yeah, basically, we saw some significant reduction in available tenders over the previous few quarters, but we definitely have seen some stabilizations, and Q3, clearly, we have seen basically pretty much a kind of flat quarter compared to a year ago. That's a good sound.
Mason Carrico, Analyst — Stephens
Mm-hmm. And I know it's always hard to call something like this, but, I mean, do you think that was, you know, the bottom that you guys have been looking for and that it can return to growth next year?
Bill McCombe, CFO
Yeah, look, I think we had an exceptional Q4 in EMEA last year, and that will be a challenging benchmark to try to beat in Q4 this year. But that was sort of an exceptional quarter last year. I think as it relates to next year, you know, hopefully we're at least... We've hit a stabilization point. You know, we're seeing a little bit of investment from biopharma in Europe. There was, I think, in 2025 in particular, a move by the pharma companies to bring investment back to the U.S. that seems to have...
Mason Carrico, Analyst — Stephens
And yeah, maybe on that point, maybe give us the puts and takes across, you know, geographies for biopharma and how you're thinking about CapEx budgets heading into.
Bill McCombe, CFO
Our sense from the sales team is that the biopharma customers have the money. We're seeing some good dialogues with the pharma companies and CROs in particular that the automation capability is particularly interesting to the CROs because they do a lot of high-throughput screening. Yeah, you know, they have been outpaced by the academic and government customers, particularly in the U.S., where there seems to be a lot of momentum driven by our new products. So I think, you know, biopharma should be solid, but, you know, I don't know that it's going to grow at the same kind of rates we've seen for academic and government.
Mason Carrico, Analyst — Stephens
And then maybe pivoting to your reagents business, I think maybe this is, I don't know, a $12 million business today. I think you previously highlighted a metric, maybe it's 150 million plus reagents flow across your existing install base today. What are some of the key initiatives you have in place to drive higher reagent capture? What do you think is, you know, a realistic capture rate over the next handful of years?
Wenbin Zhang, CEO
Yeah, as you have indicated, and more than $150 million flow through our installed base right now. And what we have been doing is to continue to expand our capability, available skills for the reagents to support the needs. Here, many of our customers are using reagents for scientific research, and here, fast delivery, available skills, and available Available regions, and all those things are important to them, and this is what we have been focusing on, trying to address, and hopefully, and eventually we'll get to the kind of level threshold that enables us to quickly penetrate into those spaces.
Mason Carrico, Analyst — Stephens
And Bill, how much of the gross margin step up you saw in Q3 is durable now that the Singapore transfer is complete? What are some puts and takes, I guess, on gross margin that we should be considering as we head into next year?
Bill McCombe, CFO
So the improvement was driven by three factors. The closure, the completion of the transfer of manufacturing capacity to Singapore and the closure of Seattle. So that's one factor that was significant. Lower tariffs and better lower cost material purchases or lower material variances. So, you know, we think all of those should be sustainable. And... You know, we think the tariff impact was at its worst in the Q3 of last year, and it's been much more stable in the quarters and lower, particularly tariffs from China. So, you know, hopefully tariffs will stabilize at this level. Um, I think, um... The, you know, manufacturing overhead savings and labor savings from the facility closure, obviously, those are permanent. And hopefully we continue to buy materials and control variances effectively. So, yeah, so it should be a sustainable increase.
Wenbin Zhang, CEO
Yeah, because we have incorporated this region for region manufacturing, and now we have our initial manufacturing across three sites here in the U.S. to support the U.S. market, Singapore, and China to support global applications. So that really enabled us to truly reduce the overall kind of tariff impact.
Bill McCombe, CFO
So in terms of puts and takes, I think going forward, revenue growth on the product side creates margin upside because our variable contribution is about 70%, and the average margin on the product side is in the low 60s. So we get some lift there as we grow revenues. In terms of takes, it's the things that disrupt unexpected events like tariff increases or cost increases, but we don't really see those. We have a stable manufacturing footprint. I think we've got good growth prospects going into next year, so hopefully we can. We can see, you know, I think now that we're at 60% level in products, you know, that had been our target. I think improvements from there will be, you know, relatively modest. The negatives, you know, I don't, I guess material cost increases is a thing to worry about. But we should be able to offset those. And you also, you know, you have continuing some labor cost pressures from things like health care, benefit increases, but we should be able to offset those with productivity. So, and then on the service side, it's basically all labor. So it's there, it's just a matter of managing your labor force growth to match the growth in the service revenue. And there's a little bit of parts, you know, we're working on improving our systems to try to eke out a little bit of productivity growth there.
Mason Carrico, Analyst — Stephens
Mm-hmm, mm-hmm. And then, maybe as we do think about 2027, you have a new platform launching, you've made improvements on gross margin, you're at adjusted even, a break-even, you know, for this year, I guess. How should we be thinking about 2027 from the standpoint of profitability and what can be done there?
Bill McCombe, CFO
Yeah, well, look, I want to be careful that we're not giving guidance today, but the way to think about profitability is, as I mentioned, for revenue growth, when we have revenue growth is a driver of improved profitability. The growth in product revenue, about 70% of that should drop through to the EBITDA line. And on service revenue, our gross margins there should be about mid-50s. So we might get a little bit of what you'll get. You get profit growth from the base. From the revenue growth times the gross margin, then you get a little bit of gross margin improvement, particularly on the product side. We have talked about our legal expense, where we expect that to be three to four million lower in Q4. Before, there are some cases that are continuing into the call. Uh, into next year, there's an ITC countersuit. Um, so that will have some expense associated with it, but that should be lower than, um, than the amount we spent this year because, you know, we had the trial in Q3, which is expensive. So hopefully we get some benefit Put on legal, and then our... And look, on the take side, we have some investments that we're making in things like the clinical products, and so there'll be some offsets, but those are the general puts and takes, and I don't want to be any more specific than that, but overall, that should add up to meaningfully improved profitability.
Mason Carrico, Analyst — Stephens
Got it. And I guess as we wrap up here, the last question is... The low and mid-end of your portfolio declined this quarter. It's been a little bit weaker. The high end has obviously been stronger. How do we kind of think about the go-forward product business from an instrument standpoint in terms of, you know, the mix of what's driving it, high versus mid to low? What initiatives do you have to kind of improve the mid to low? How do we think about ASP versus placements? Sure.
Wenbin Zhang, CEO
And with regarding to the strategy for the high end, which is where we have been strong and we already talked a lot about it, like borderless EVO, EVO 2. And then for the mid-entry level, our strategy is to focus on developing solutions as a full solution to enable the segment which really aim for ease of use to help them to To do the experiment, to do the scientific research here, we will lump the instrument together with the reagents as well as the software as a whole package, leveraging Citec Cloud to support, help our customer base, so that will expand our penetration into the customer base.
Bill McCombe, CFO
Yeah, that's the and we're, you know, we're adding significant sales resources and marketing dollars behind that business, too. As one bit says, we're not going to just go to the customer and say, here's a box, we're going to the customer and say, here's an instrument reagent software, and it can solve that problem. So that's the, we think, is the key approach in that market. It has been more price competitive than the other segments. So that's been the issue there.
Mason Carrico, Analyst — Stephens
All right. We'll wrap up there. Thank you, guys.
Bill McCombe, CFO
Thanks very much.